# ONTRK (NCT03182257)

> Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03182257
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Ono Pharmaceutical Co., Ltd.
- Conditions: Solid Tumor
- Interventions: ONO-7579
- Enrollment: 1
- Primary outcome: Part A: Incidence, nature and severity of Adverse Events
- Primary outcome: Part A: Clinically significant changes in physical examinations
- Primary outcome: Part A: Clinically significant changes in neurological examinations
- Primary outcome: Part A: Clinically significant changes in vital signs and electrocardiogram - including the evaluation of the QT interval
- Primary outcome: Part B: Overall Response Rate (ORR)

## Commentary we found

- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ontrk-nct03182257